Physician profile
Jose E Castaneda
NPI 1699840264
$3,131.11
in general payments reported to CMS, 2019-2025
21 companies · $951 in 2025
The $951 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $344 · 2023: $659 · 2024: $820 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,211.25 | 2021-2025 | |
| Novo Nordisk INC | $1,065.72 | 2022-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $220.32 | 2021-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $157.10 | 2021-2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $107.73 | 2021-2023 | Livalo, Seglentis |
| Azurity Pharmaceuticals, INC. | $55.07 | 2025 | Azmiro |
| Smith+Nephew, INC. | $41.17 | 2025 | Grafix Pl |
| Amarin Pharma, INC. | $40.92 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $28.55 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.59 | 2022 | |
| Alkermes, INC. | $25.60 | 2021 | |
| Abbott Laboratories | $22.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.62 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.54 | 2025 | Hetlioz, Fanapt |
| Jazz Pharmaceuticals INC. | $14.67 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.06 | 2021 | |
| Gilead Sciences, INC. | $13.85 | 2021 | |
| Tris Pharma INC | $13.66 | 2024 | Dyanavel Xr |
| Clarus Therapeutics INC. | $13.51 | 2021 | |
| Genentech USA, INC. | $13.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Castaneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.